Last updated: 2026-09-09 04:54:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Anika Therapeutics Inc. (ANIK) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $21,03, with a market capitalization of $278,50M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $8,37 to $22,88. This page covers its latest market performance, valuation, price trends and company information.
$278,50M | |
$20,58 | |
$75,72 | |
$2,96 | |
$20,81 | |
63,24K | |
96,86K | |
-- | |
$22,88 | |
$8,37 | |
-- | |
-- |
Anika Therapeutics Inc. (ANIK) last closed at $20,81 as of 2026-09-08 23:31:00, unchanged from the previous close of $20,81.
During the latest regular trading session, ANIK traded between $2,96 and $75,72, with a volume of 63,24K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Anika Therapeutics Inc. (ANIK) moved from $20,84 to $21,03, representing a gain of 0,89% ($0,18).
The stock traded between $20,13 and $21,97 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 105,28 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 87,2%
ANIK is currently trading at $21,03, placing it 87,2% of the way from its 52-week low of $8,37 to its 52-week high of $22,88. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 235 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Anika Therapeutics Inc. (ANIK) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.